导师基本信息
- 姓名：何忠虎
- 性别：男
- 民族：汉族
- 科室：遗传学研究室
- 职称：研究员,副教授
- 专业：流行病与卫生统计学
- E-MAIL： zhonghuhe@foxmail.com
学术论文 | 综述述评 | 出版专著 | 研究方向 | 科研项目 | 招生计划
Liu M, Yang W, Guo C, Liu Z, Li F, Liu A, Yang H, Shen L, Wu Q, Duan L, Wang H, Tian H, Shi C, Pan Y, Liu Y, Liu F, Weiss NS, Cai H, He Z, Ke Y. Effectiveness of Endoscopic Screening on Esophageal Cancer Incidence and Mortality: A 9-Year Report of the Endoscopic Screening for Esophageal Cancer in China (ESECC) Randomized Trial,J Clin Oncol,J Clin Oncol. 2024 May 10;42(14):1655-1664. doi: 10.1200/JCO.23.01284. Epub 2024 Mar 8.
He Z, Ke Y. Challenge and future of cancer screening in China: Insights from esophageal cancer screening practice,Chin J Cancer Res,Chin J Cancer Res. 2023 Dec 30;35(6):584-594. doi: 10.21147/j.issn.1000-9604.2023.06.03.
Liu F, Yang W, He Y, Yang W, Chen L, Xu R, Liu Z, Ke J, Hou B, Zhang L, Lin M, Liang L, Huang Y, Zhang L, Zhang F, Cai F, Xu H, Liu M, Pan Y, Liu Y, He Z, Ke Y. Surgical quality determines the long-term survival superiority of right over left thoracic esophagectomy for localized esophageal squamous cell carcinoma patients: a real-world multicenter study,Int J Surg,Int J Surg. 2024 Feb 1;110(2):675-683. doi: 10.1097/JS9.0000000000000897.
Huang Y, Liu F, Xu R, Zhou F, Yang W, He Y, Liu Z, Hou B, Liang L, Zhang L, Liu M, Pan Y, Liu Y, He Z, Ke Y. Postoperative serum squamous cell carcinoma antigen and carcinoembryonic antigen predict overall survival in surgical patients with esophageal squamous cell carcinoma,Front Oncol,Front Oncol. 2023 Sep 22;13:1263990. doi: 10.3389/fonc.2023.1263990. eCollection 2023.
Bai XM, He ZH, Wu H, Yang W, Wang S, Zhang ZY, Wu W, Yan K, Chen MH, Nahum Goldberg S. An evaluation of 20-year survival of radiofrequency ablation for hepatocellular carcinoma as first-line treatment,Eur J Radiol,Eur J Radiol. 2023 Nov;168:111094. doi: 10.1016/j.ejrad.2023.111094. Epub 2023 Sep 13.
Liu M, Qi Z, Zhou R, Guo C, Liu A, Yang H, Li F, Duan L, Shen L, Wu Q, Liu Z, Pan Y, Liu F, Liu Y, Cai H, He Z, Ke Y. How should extra-large Lugol-unstained lesions of the esophagus be treated? Results from a population-based cohort study,Cancer Med,Cancer Med. 2023 Oct;12(19):20129-20139. doi: 10.1002/cam4.6592. Epub 2023 Sep 21.
Qin J, Liu M, Liu A, Guo C, Qi Z, Zhou R, Yang H, Li F, Duan L, Shen L, Wu Q, Liu Z, Pan Y, Liu F, Liu Y, Cai H, He Z, Ke Y. Lugol-unstained lesions location in the esophagus affects the detection rate of malignancy: a population-based study,J Gastroenterol Hepatol,J Gastroenterol Hepatol. 2023 Dec;38(12):2167-2173. doi: 10.1111/jgh.16356. Epub 2023 Sep 19.
Liu Z, Liu M, Liu Y, Zhou R, Abliz A, Yuan W, Guo C, Zhang L, He W, Zheng H, Huang Y, Pan Y, Liu F, Hu Z, Chen H, Cai H, He Z, Ke Y. Absence of Lugol staining indicates initiation of esophageal squamous cell carcinoma: A combined genomic and epidemiologic study,Cell Rep Med,Cell Rep Med. 2023 Sep 19;4(9):101168. doi: 10.1016/j.xcrm.2023.101168. Epub 2023 Aug 24.
Li F, Liu M, Guo C, Xu R, Li F, Liu Z, Pan Y, Liu F, Liu Y, Cai H, He Z, Ke Y. Cost-effectiveness of precision screening for esophageal cancer based on individualized risk stratification in China: Real-world evidence from the ESECC trial,Front Oncol,Front Oncol. 2022 Nov 30;12:1002693. doi: 10.3389/fonc.2022.1002693. eCollection 2022.
Liu Z, Zheng H, Liu M, He Y, Chen Y, Ji P, Fang Z, Xiao P, Li F, Guo C, Yin W, Pan Y, He Z, Ke Y. Development and External Validation of an Improved Version of the Diagnostic Model for Opportunistic Screening of Malignant Esophageal Lesions,Cancers (Basel),Cancers (Basel). 2022 Nov 30;14(23):5945. doi: 10.3390/cancers14235945.
Qi Z, Liu M, Zhou R, Guo C, Liu A, Yang H, Li F, Duan L, Shen L, Wu Q, Wu N, Liu Z, Pan Y, Liu F, Liu Y, Cai H, He Z, Ke Y. Multiple Lugol-unstained lesions predict higher cumulative risk of malignance in the esophagus,J Gastroenterol Hepatol,J Gastroenterol Hepatol. 2023 Mar;38(3):416-423. doi: 10.1111/jgh.16075. Epub 2022 Dec 7.
Liang L, Liu F, He Z, Ke Y. ASO Author Reflections: A Novel Blood-Based Predictor (MF-A) That Independently Influences the Prognosis of ESCC Patients Receiving Esophagectomy,Ann Surg Oncol,Ann Surg Oncol. 2022 Sep;29(9):5634-5635. doi: 10.1245/s10434-022-11428-0. Epub 2022 Jul 11.
Liu M, Liu Y, Zhou R, Liu Z, Guo C, Xu R, Li F, Liu A, Yang H, Zhang S, Shen L, Duan L, Wu Q, Zhao M, Su H, Liu F, Pan Y, Cai H, He Z, Ke Y. Absence of NOTCH1 mutation and presence of CDKN2A deletion predict progression of esophageal lesions,J Pathol,J Pathol. 2022 Sep;258(1):38-48. doi: 10.1002/path.5970. Epub 2022 Jun 30.
Liu M, Zhou R, Liu Z, Guo C, Xu R, Zhou F, Liu A, Yang H, Li F, Duan L, Shen L, Wu Q, Zheng H, Tian H, Liu F, Liu Y, Pan Y, Chen H, Hu Z, Cai H, He Z, Ke Y. Update and validation of a diagnostic model to identify prevalent malignant lesions in esophagus in general population,EClinicalMedicine,EClinicalMedicine. 2022 Apr 16;47:101394. doi: 10.1016/j.eclinm.2022.101394. eCollection 2022 May.
Li F, Hu Y, Guo C, Lei L, Li F, Liu M, Liu Z, Pan Y, Liu F, Liu Y, Hu Z, Chen H, He Z, Ke Y. Economic Burden Conferred by Population-Level Cancer Screening on Resource-Limited Communities: Lessons From the ESECC Trial,Front Oncol,Front Oncol. 2022 Mar 21;12:849368. doi: 10.3389/fonc.2022.849368. eCollection 2022.
Tian H, Liu W, Song Y, Mi L, Liu Z, Liu M, Guo C, Liu F, Liu Y, Pan Y, Zhu J, He Z, Ke Y. The Incidence of Lymphoma in Beijing: Comparing Results from MIS-CASS (2019) and Beijing Cancer Registry (2017),China CDC Wkly,China CDC Wkly. 2021 Dec 24;3(52):1118-1125. doi: 10.46234/ccdcw2021.269.
Liang L, Liu F, Yang W, Yang W, Chen L, He Y, Liu Z, Zhang L, Zhang F, Cai F, Xu H, Lin M, Liu M, Pan Y, Liu Y, Hu Z, Chen H, He Z, Ke Y. Combined Mean Corpuscular Hemoglobin, Fibrinogen, and Albumin (MF-A) Is a Novel Prognostic Marker in Patients with Resectable Esophageal Squamous Cell Carcinoma,Ann Surg Oncol,Ann Surg Oncol. 2022 Sep;29(9):5626-5633. doi: 10.1245/s10434-022-11415-5. Epub 2022 Feb 18.
Liu F, Yang W, Yang W, Xu R, Chen L, He Y, Liu Z, Zhou F, Hou B, Zhang L, Zhang L, Zhang F, Cai F, Xu H, Lin M, Liu M, Pan Y, Liu Y, Hu Z, Chen H, He Z, Ke Y. Minimally Invasive or Open Esophagectomy for Treatment of Resectable Esophageal Squamous Cell Carcinoma? Answer From a Real-world Multicenter Study,Ann Surg,Ann Surg. 2023 Apr 1;277(4):e777-e784. doi: 10.1097/SLA.0000000000005296. Epub 2021 Nov 11.
Zhou R, Zheng H, Liu M, Liu Z, Guo C, Tian H, Liu F, Liu Y, Pan Y, Chen H, Hu Z, Cai H, He Z, Ke Y. Development and validation of a questionnaire-based risk scoring system to identify individuals at high risk for gastric cancer in Chinese populations,Chin J Cancer Res,Chin J Cancer Res. 2021 Dec 31;33(6):649-658. doi: 10.21147/j.issn.1000-9604.2021.06.02.
Yang W, Liu F, Xu R, Yang W, He Y, Liu Z, Zhou F, Heng F, Hou B, Zhang L, Chen L, Zhang F, Cai F, Xu H, Lin M, Liu M, Pan Y, Liu Y, Hu Z, Chen H, He Z, Ke Y. Is Adjuvant Therapy a Better Option for Esophageal Squamous Cell Carcinoma Patients Treated With Esophagectomy? A Prognosis Prediction Model Based on Multicenter Real-World Data,Ann Surg,Ann Surg. 2023 Jan 1;277(1):e61-e69. doi: 10.1097/SLA.0000000000004958. Epub 2021 Jun 2.
M. Liu#, Z. Liu#, F. Liu#, C. Guo, R. Xu, F. Li, A. Liu, H. Yang, S. Zhang, L. Shen, L. Duan, Q. Wu, C. Cao, Y. Pan, Y. Liu, J. Li, H. Cai, Z. He* and Y. Ke*. Absence of Iodine Staining Associates With Progression of Esophageal Lesions in a Prospective Endoscopic Surveillance Study in China.,Clin Gastroenterol Hepatol,18(7): 1626-1635.
Liu F#, Liu M#, Liu Y#, Guo C, Zhou Y, Li F, Xu R, Liu Z, Deng Q, Li X, Zhang C, Pan Y, Ning T, Dong X, Hu Z, Bao H, Cai H, Silva IDS*, He Z*, and Ke Y*,Chin J Cancer Res,32(6): 742-754
Z. He and Y. Ke, Precision screening for esophageal squamous cell carcinoma in China.,Chin J Cancer Res,32(6):673-682
Z. Liu#, C. Guo#, Y. He#, Y. Chen#, P. Ji#, Z. Fang#, F. Li, Y. Tang, X. Chen, P. Xiao, C. Wang, W. Yin, H. Guo, M. Liu, Y. Pan, F. Liu, Y. Liu, Z. He*, and Y. Ke*, A clinical model predicting the risk of esophageal high-grade lesions in opportunistic screening: a multicenter real-world study in China.,Gastrointest Endosc,91(6):1253-1260.
M. Wang#, M. Liu#, F. Li, C. Guo, Z. Liu, Y. Pan, Y. Liu, F. Liu, H. Cai, Y. Wu, Z. He*, and Y. Ke*, Gender heterogeneity in dyslipidemia prevalence, trends with age and associated factors in middle age rural Chinese.,Lipids Health Dis,19(1): 135.
H. Tian#, W. Yang#, Y. Hu#, Z. Liu#, L. Chen, L. Lei, F. Zhang, F. Cai, H. Xu, M. Liu, C. Guo, Y. Chen, P. Xiao, J. Chen, P. Ji, Z. Fang, F. Liu, Y. Liu, Y. Pan, I. Dos-Santos-Silva, Z. He*, and Y. Ke*, Estimating cancer incidence based on claims data from medical insurance systems in two areas lacking cancer registries in China.,EClinicalMedicine,20: 100312.
Liu M#, Zhou R#, Liu Z#, Guo C, Xu R, Zhou F, Liu A, Yang H, Li F, Duan L, Shen L, Wu Q, Zheng H, Tian H, Liu F, Liu Y, Pan Y, Chen H, Hu Z, Cai H, He Z*, and Ke Y*. Update and validation of a diagnostic model to identify prevalent malignant lesions in esophagus in general population.,EClinicalMedicine,47:101394.
Li F, Hu Y, Guo C, Lei L, Li F, Liu M, Liu Z, Pan Y, Liu F, Liu Y, Hu Z, Chen H, He Z*, and Ke Y*. Economic Burden Conferred by Population-Level Cancer Screening on Resource-Limited Communities: Lessons from the ESECC Trial.,Front Oncol,12:849368
Zhou R#, Zheng H#, Liu M#, Liu Z#, Guo C, Tian H, Liu F, Liu Y, Pan Y, Chen H, Hu Z, Cai H, He Z*, and Ke Y*. Development and validation of a questionnaire-based risk scoring system to identify individuals at high risk for gastric cancer in Chinese populations.,Chin J Cancer Res,33(6):649-658.
Wang M#, Liu M#, Guo C, Li F, Liu Z, Pan Y, Liu F, Liu Y, Bao H, Hu Z, Cai H, He Z*, and Ke Y*. Association of early-life undernutrition and risk of dyslipidemia in adulthood: a population-based cohort study.,BMC Public Health,21(1): 2129.
Wang M#, Liu F#, Pan Y#, Xu R, Li F, Liu A, Yang H, Duan L, Shen L, Wu Q, Liu Y, Liu M, Liu Z, Hu Z, Chen H, Cai H, He Z*, and Ke Y*. Tumor-associated autoantibodies in ESCC screening: Detecting prevalent early-stage malignancy or predicting future cancer risk?,EBioMedicine,73: 103674.
Liu M#, Zhou R#, Guo C, Xu R, Liu A, Yang H, Li F, Duan L, Shen L, Wu Q, Liu Z, Liu F, Liu Y, Pan Y, Cai H, Weiss NS*, He Z* and Ke Y*. Size of Lugol-unstained lesions as a predictor for risk of progression in premalignant lesions of the esophagus.,Gastrointest Endosc,93(5):1065-1073.
He Z, Ke Y. Challenge and future of cancer screening in China: Insights from esophageal cancer screening practice,Chin J Cancer Res,Chin J Cancer Res. 2023 Dec 30;35(6):584-594. doi: 10.21147/j.issn.1000-9604.2023.06.03.
He Z, Ke Y. Precision screening for esophageal squamous cell carcinoma in China,Chin J Cancer Res,Chin J Cancer Res. 2020 Dec 31;32(6):673-682. doi: 10.21147/j.issn.1000-9604.2020.06.01.
流行病学研究实例（第五卷）, 参编, 人民卫生出版社, 2021.6
整合肿瘤学（基础卷）, 参编, 世界图书出版公司, 2021.6
精准健康管理, 参编, 北京大学医学出版社, 2020.10
胃癌高低发区影响因素的综合调查, 子课题负责人, 2020.1.1～2022.12.31, 国家科技部
基于前瞻性队列的食管癌早期预警生物标志物筛选及风险预测研究, 2020.11.1～2023.10.31, 北京市自然科学基金京津冀基础研究合作专项
食管癌专病队列研究—高发现场食管癌及其癌前病变人群前瞻性队列研究, 子课题负责人, 2016.7.1～2020.12.31, 国家重点研发计划“精准医学研究 (2016YFC0901404)
基于前瞻性队列的食管癌早期预警生物标志物筛选及风险预测研究, 课题负责人, 2021.1.1～2022.12.31, 北京市百千万人才工程
基于前瞻性人群队列的食管癌早期预警生物标志物筛选及风险预测研究, 课题负责人, 2021.1.1～2024.12.31, 国家自然科学基金面上项目
基于前瞻性人群队列的食管癌早期预警生物标志物筛选及风险预测研究, 课题负责人, 2021.1.1～2024.12.31, 国家自然基金面上项目
常见恶性肿瘤联合早筛模式的建立及卫生经济学评价, 子课题负责人, 2021.12.1～2024.11.30, 国家重点研发计划
社会任职
- 中国抗癌协会食管癌整合防筛专业委员会常委
- 中国医师协会循证医学专业委员会委员
- 中国医疗保健国际交流促进会健康数据与数字医学分会常委
- 中国抗癌协会肿瘤精准治疗专业委员会 委员
- 北京癌症防治学会精准预防专业委员会 副主任委员
学习、工作经历
- 2019.8.1～，北京大学肿瘤医院 研究员、博士生导师
- 2016.8.1～，遗传室副主任、基础教研室副主任
- 2011.5.2～2019.7.31，北京大学肿瘤医院 副研究员 硕士生导师
- 2010.9.2～2011.8.2，美国华盛顿大学（UW）流行病学系 访问学者
- 2008.8.2～2011.5.2，北京大学临床肿瘤学院 助理研究员
